SCHEMBL5608115

SCHEMBL5608115

COc1ccccc1C(=O)NCc1ccc(CC(N)C(=O)O)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 6/20 0.71
TP53 P04637 1/20 0.71
GLA P06280 1/20 0.71
POLB P06746 1/20 0.62
PPARA Q07869 9/20 0.57
PPARG P37231 4/20 0.57
LMNA P02545 3/20 0.56
ALDH1A1 P00352 3/20 0.54
MAPK1 P28482 2/20 0.54
HTT P42858 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
KDM4E B2RXH2 1/20 0.53
RAB9A P51151 1/20 0.53
NOD2 Q9HC29 1/20 0.53
PPARD Q03181 2/20 0.53
CTSD P07339 1/20 0.52
SGMS2 Q8NHU3 1/20 0.52
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5608111 1.00 HPGD (0.71) HPGDTP53GLAPOLBPPARA
SCHEMBL5607120 0.90 HPGD (0.56) HPGDTP53GLAPOLBPPARA
SCHEMBL5607101 0.90 HPGD (0.56) HPGDTP53GLAPOLBPPARA
SCHEMBL5607803 0.85 MAPT (0.60) TP53LMNAALDH1A1MAPK1SMN1; SMN2
SCHEMBL5607808 0.85 MAPT (0.60) TP53LMNAALDH1A1MAPK1SMN1; SMN2
SCHEMBL5607822 0.85 PPARA (0.56) HPGDTP53GLAPPARAPPARG
SCHEMBL5080127 0.85 PPARA (0.56) HPGDTP53GLAPPARAPPARG
SCHEMBL5607964 0.85 PPARA (0.65) PPARAPPARGPPARD
SCHEMBL5607956 0.85 PPARA (0.65) PPARAPPARGPPARD
SCHEMBL27604453 0.84 HPGD (1.00) HPGDTP53GLAPOLBPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101400699-A Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions BRISTOL MYERS SQUIBB CO (US) 2009-04-01 CN claimed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 US claimed
CN-101400699-A Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions BRISTOL MYERS SQUIBB CO (US) 2009-04-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS GLP1R, GIPR, IAPP HPGD 2659/4885TP53 4432/4885GLA 1050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.